Vanoxerine

Drug Profile

Vanoxerine

Alternative Names: Boxeprazine; GBR-12909

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Gist-Brocades
  • Developer Laguna Pharmaceuticals; Novo Nordisk
  • Class Antidepressants; Antiparkinsonians; Piperazines; Small molecules
  • Mechanism of Action Dopamine plasma membrane transport protein antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atrial fibrillation; Cocaine abuse; Major depressive disorder; Parkinson's disease; Peptic ulcer

Most Recent Events

  • 04 Dec 2015 Discontinued - Phase-III for Atrial fibrillation in USA, Bulgaria, Hungary, Israel, Netherlands, Poland and Russia (PO)
  • 01 Sep 2015 Phase-III clinical trials in Atrial fibrillation in USA, Russia, Israel, Bulgaria, Hungary (PO)
  • 06 Jun 2015 Laguna Pharmaceuticals plans a phase III trial in Atrial fibrillation in USA (NCT02454283)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top